• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by DURECT Corporation

    11/14/24 4:15:46 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRRX alert in real time by email
    S-8 1 drrx-s8-nov_2024.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on November 14, 2024

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    DURECT CORPORATION

    (Exact name of Registrant as specified in its charter)

     

    Delaware

    94-3297098

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    10240 Bubb Road

    Cupertino, CA 95014

    (Address of Principal Executive Offices)

    DURECT Corporation 2000 Stock Plan, as amended

    (Full title of the plan)

    James E. Brown

    Chief Executive Officer

    DURECT Corporation

    10240 Bubb Road

    Cupertino, CA 95014

    (Name and address of agent for service)

    (408) 777-1417

    (Telephone number, including area code, of agent for service)

    Copy to:

    Stephen B. Thau

    Orrick, Herrington & Sutcliffe LLP
    51 West 52
    nd Street
    New York, NY 10019

    (212) 506-5000

    (Calculation of Registration Fee on following page)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging Growth Company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐


     

    REGISTRATION OF ADDITIONAL SECURITIES

    PURSUANT TO GENERAL INSTRUCTION E

    DURECT Corporation (the “Registrant”) is filing this Registration Statement with the U.S. Securities and Exchange Commission (the “Commission”) to register an additional 2,000,000 shares of common stock, $0.0001 par value per share (“Common Stock”), issuable to eligible persons under its 2000 Stock Plan, as amended (the “Plan”). An amendment of the Plan, including an increase of 2,000,000 shares of Common Stock available for issuance thereunder, was approved at the Registrant’s 2024 Annual Meeting of Stockholders held on September 25, 2024 as previously reported on the Registrant’s Form 8-K filed with the Commission on September 26, 2024.

    Pursuant to General Instruction E of Form S-8, the Registrant incorporates by reference into this Registration Statement, except to the extent supplemented, amended or superseded by the information set forth herein, the contents of the Registration Statements on Form S-8, including all attachments and exhibits thereto, relating to the Plan as previously filed with the Commission by the Registrant on October 5, 2000, May 18, 2001, April 12, 2002, August 29, 2003, November 12, 2004, May 6, 2005, May 17, 2006, August 8, 2007, August 12, 2008, August 4, 2009, May 10, 2010, August 5, 2011, August 8, 2014, August 2, 2016, August 2, 2018, and August 5, 2022 (Registration Nos. 333-47400, 333-61224, 333-86110, 333-108390, 333-120405, 333-124701, 333-134200, 333-145244, 333-152968, 333-161025, 333-166700, 333-176113, 333-197980, 333-212842, 333-226524 and 333-266590, respectively) (collectively, the “Prior Registration Statements”). This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.


     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

    The following documents, which have been filed with the Commission, are incorporated by reference herein and made a part hereof:

    a. The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Annual Report”), which includes audited consolidated financial statements for the fiscal year ended December 31, 2023, filed with the Commission, pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on March 28, 2024.

    b. All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act, since the end of the fiscal year covered by the audited financial statements described in (a) above.

    c. The description of the Common Stock contained in Exhibit 4.1 of the Annual Report, including any amendment or report filed for the purpose of updating such description.

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be part hereof from the date of the filing of such documents, except as to specific sections of such statements as set forth therein.

    Unless expressly incorporated into this Registration Statement, a report (or portion thereof) furnished on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement, except as to specific sections of such statements as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    To the extent that any proxy statement or Form 8-K is incorporated herein by reference, such incorporation shall not include any information contained in such proxy statement or Form 8-K which is not, pursuant to the Commission’s rules, deemed to be “filed” with the Commission or subject to the liabilities of Section 18 of the Exchange Act.

    ITEM 8.

    EXHIBITS

    Exhibit

    Number

    Exhibit Title

    5.1*

    Opinion of Orrick, Herrington & Sutcliffe LLP.

    23.1*

    Consent of Orrick, Herrington & Sutcliffe LLP (included in Exhibit 5.1).

    23.2*

    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.

    24.1*

    Powers of Attorney (included in the signature page to this Registration Statement).

    99.1

    DURECT Corporation 2000 Stock Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 000-31615) filed on September 26, 2024).

    107*

    Filing Fee Exhibit.

    * Filed herewith.


     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cupertino, State of California, on November 14, 2024.

    DURECT CORPORATION

    By:

    /s/ james e. brown

    James E. Brown

    President, Chief Executive Officer and Director

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned directors and officers of the Registrant do hereby constitute and appoint James E. Brown and Timothy M. Papp, and each of them severally, our true and lawful attorneys-in-fact and agents, acting alone with full power of substitution and resubstitution, to do any and all such acts and things in our name and on our behalf in our capacities as directors and officers and to execute any and all instruments for us and in our names in the capacities indicated below, which said attorneys and agents, or either of them, may deem necessary or advisable to enable said corporation to comply with the Securities Act of 1933, as amended (“Securities Act”), and any rules, regulations and requirements of the Commission, in connection with this Registration Statement on Form S-8 under the Securities Act, including specifically, but without limitation, power and authority to sign for us or in any of our names and in the capacities indicated below any and all amendments (including post effective amendments) to this Registration Statement, or any related Registration Statement that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act; and we do hereby ratify and confirm all that the said attorneys and agents, or either of them, shall do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature

    Title

    Date

    /s/ james e. brown

    President, Chief Executive Officer and Director

     November 14, 2024

    James E. Brown

    (Principal Executive Officer)

    /s/ Timothy M. Papp

    Chief Financial Officer

    November 14, 2024

    Timothy M. Papp

    (Principal Financial and Accounting Officer)

    /s/ Mohammad Azab

    Director

    November 14, 2024

    Mohammad Azab

    /s/ terrence f. blaschke

    Director

    November 14, 2024

    Terrence F. Blaschke

    /s/ Gail M. farfel

    Director

    November 14, 2024

    Gail M. Farfel

    /s/ Peter S. Garcia

    Director

    November 14, 2024

    Peter S. Garcia

    /s/ Gail J. Maderis

    Director, Chairperson of the Board

    November 14, 2024

    Gail J. Maderis

    /s/ judith j. Robertson

    Director

    November 14, 2024

    Judith J. Robertson


     

     


    Get the next $DRRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DRRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health

    Bausch Health will pay $1.75 per share plus up to $350 million in aggregate sales milestones Transaction expected to close in the third quarter of 2025 CUPERTINO, Calif., Aug. 12, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the second quarter ended June 30, 2025 and provided an update on the previously announced acquisition of DURECT by Bausch Health Companies Inc. (Bausch Health). Recent business highlights and updates: In July 2025, DURECT announced that it entered into an Agreement and Plan of Merger with Bausch Health America

    8/12/25 4:30:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

    Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initiation Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 CUPERTINO, Calif., May 13, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the first quarter ended March 31, 2025 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and l

    5/13/25 4:05:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

    3/26/25 4:05:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    SEC Filings

    View All

    SEC Form 15-12G filed by DURECT Corporation

    15-12G - DURECT CORP (0001082038) (Filer)

    9/22/25 6:36:16 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by DURECT Corporation

    EFFECT - DURECT CORP (0001082038) (Filer)

    9/15/25 12:15:04 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by DURECT Corporation

    S-8 POS - DURECT CORP (0001082038) (Filer)

    9/11/25 11:14:47 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Durect with a new price target

    HC Wainwright & Co. reiterated coverage of Durect with a rating of Buy and set a new price target of $6.00

    5/5/21 6:31:29 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital reiterated coverage on Durect with a new price target

    Chardan Capital reiterated coverage of Durect with a rating of Buy and set a new price target of $8.00 from $7.00 previously

    2/3/21 8:15:53 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by President & CEO Brown James E

    4/A - DURECT CORP (0001082038) (Issuer)

    9/16/25 2:16:30 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Robertson Judith J. closing all direct ownership in the company (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    9/12/25 9:34:05 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Brown James E returned 96,959 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    9/12/25 8:47:03 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for POSIMIR

    Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

    2/2/21 7:24:30 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Asen R Scott bought $11,357 worth of shares (5,917 units at $1.92), increasing direct ownership by 0.22% to 2,672,529 units (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    8/26/25 3:41:18 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Asen R Scott bought $386,666 worth of shares (204,220 units at $1.89), increasing direct ownership by 5% to 2,666,612 units (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    8/22/25 6:10:18 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DURECT Corporation

    SC 13G/A - DURECT CORP (0001082038) (Subject)

    11/19/24 5:10:25 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by DURECT Corporation

    SC 13G - DURECT CORP (0001082038) (Subject)

    3/27/24 3:15:14 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by DURECT Corporation

    SC 13G - DURECT CORP (0001082038) (Subject)

    2/16/24 4:09:22 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Leadership Updates

    Live Leadership Updates

    View All

    KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

    KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

    9/4/24 8:00:00 AM ET
    $AVTX
    $DRRX
    $HALO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Medicinal Chemicals and Botanical Products

    DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

    CUPERTINO, Calif., March 21, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.  Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election and will retire from the board on June 21, 2023 when his current term as a board member expires.    "We thank Dave for his many years of service on the DURECT Board and wish him well," stated James E. Brown, D.V.M., President and CEO of DURECT.  "Gail is a seasoned biopharmaceutical executive and we have benefitted from her innovative and strategic thinking as a board member since January

    3/21/23 4:30:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

    CUPERTINO, Calif., July 5, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment of Timothy M. Papp as its Chief Financial Officer. In this new role, Mr. Papp will direct and oversee all financial and capital markets activities including accounting, financial reporting, financial planning and analysis, financial strategy, and investor relations. "We are excited to welcome Tim to our executive leadership team, as he brings his deep understanding of corporate finance and corporate value drivers to DURECT," stated James E. Brown,

    7/5/22 8:30:00 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Financials

    Live finance-specific insights

    View All

    DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

    3/26/25 4:05:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

    CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

    3/19/25 4:30:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

    -     Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation -     Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif., Nov. 13, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute o

    11/13/24 4:01:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care